Willingness to Pay for Improvements in Chronic Long-Acting Insulin Therapy in Individuals With Type 1 or Type 2 Diabetes Mellitus
Authors:
- Andrew LloydALAndrew Lloyd
- Beenish NafeesBNBeenish Nafees
- Anthony H. BarnettABAnthony H. Barnett
- Simon HellerSHSimon Heller
- Uffe J. PlougUPUffe J. Ploug
- Morten LammertMLMorten Lammert
- Mette BøgelundMBMette Bøgelund
- 1 September 2011
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 33 (9) , 1258-1267
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Preferences and utilities for the symptoms of moderate to severe allergic asthmaThe European Journal of Health Economics, 2007
- Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetesDiabetes, Obesity and Metabolism, 2006
- How diabetes and insulin therapy affects the lives of people with type 1 diabetesEuropean Diabetes Nursing, 2006
- Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 DiabetesClinical Therapeutics, 2006
- A Meta-analysis of Hypothetical Bias in Stated Preference ValuationEnvironmental and Resource Economics, 2005
- The Importance of Drug Adverse Effects Compared with Seizure Control for People with EpilepsyPharmacoEconomics, 2005
- Private and social time preferences for health and money: an empirical estimationHealth Economics, 2001
- The Economic Value of a New Insulin Preparation, Humalog?? Mix 25???PharmacoEconomics, 2000
- Economic Evaluation of Insulin Lispro versus Neutral (Regular) Insulin Therapy Using a Willingness-To-Pay ApproachPharmacoEconomics, 1998
- Stated preference and choice models applied to recreation research: A reviewLeisure Sciences, 1990